Cover Image
市场调查报告书

肺癌治疗市场上已上市药物及开发平台药物候补分析

A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market

出版商 Frost & Sullivan 商品编码 323658
出版日期 内容信息 英文 74 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
肺癌治疗市场上已上市药物及开发平台药物候补分析 A Product and Pipeline Analysis of the Lung Cancer Therapeutics Market
出版日期: 2015年01月28日 内容信息: 英文 74 Pages
简介

肺癌治疗市场上,发现新的标靶治疗药,预计将取代传统的治疗方法。高成本效率的治疗及标靶治疗成为该市场的未满足需求。

本报告提供肺癌治疗的已上市药物及开发平台药物候补的相关调查、各种药物类别、作用机制、临床试验的时间轴及结果、产品的销售/核准时间表、流行病学、其他重要数据、各开发阶段的竞争环境、关注的企业、产业趋势分析等详细内容汇整。

第1章 摘要整理

第2章 调查手法、调查范围

第3章 市场概要

  • 市场概要:各种类
  • 最近的市场发展
  • 值得注意的企业
  • 主要的M&A、联盟的评估
  • 改变市场流程的策略

第4章 流行病学

第5章 竞争情形

  • 竞争环境:已上市药物及开发平台第三阶段&已申请药物
  • 竞争环境:开发平台第一阶段及第二阶段药物
  • 到产品的销售/核准为止的时间表
  • 专利到期的时间轴
  • 竞争环境:枢纽试验

第6章 已上市产品

第7章 开发平台药物分析

第8章 产品开发动态即时看板系统:最近核准的药物、开发后期的开发平台药物候补

  • 产品开发动态即时看板系统:TarcevaR (Erlotinib)-Roche Group
  • 产品开发动态即时看板系统:GilotrifR (Afatinib)-Boehringer Ingelheim
  • 产品开发动态即时看板系统:AvastinR (Bevacizumab)-Genentech Inc. (Roche Group)
  • 产品开发动态即时看板系统:AlimtaR (Pemetrexed)-Eli Lilly and Company
  • 产品开发动态即时看板系统:XALKORIR (Crizotinib)-Pfizer Inc.
  • 产品开发动态即时看板系统:AP26113-Ariad Pharmaceuticals, Inc.
  • 产品开发动态即时看板系统:Necitumumab-Eli Lilly and Company
  • 产品开发动态即时看板系统:Nivolumab-Bristol-Myers Squibb Company、小野药品工业

第9章 总论

  • 结论
  • 免责声明

第10章 附录

第11章 关于FROST & SULLIVAN

目录
Product Code: MAC3-01-00-00-00

Discovery of New Targeted Therapies Will Replace Conventional Therapies

This study assesses marketed and in-research products and combination regimens for the lung cancer therapeutics market. Segmentation by drug class is provided, along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented by their mechanism of action against cancer. Cost-effective treatments and targeted therapies are the key unmet needs of the market.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Executive Summary
  • 2. Executive Summary (continued)
  • 3. Executive Summary (continued)

2. METHODOLOGY AND SCOPE

  • 1. Methodology and Scope

3. MARKET OVERVIEW

  • 1. Market Overview-Segmentation
  • 2. Market Overview-Segmentation (continued)
  • 3. Market Overview-Segmentation (continued)
  • 4. Recent Market Developments
  • 5. Companies to Watch
  • 6. Key Merger, Acquisition, and Partnership Assessment
  • 7. Game-changing Strategies

4. EPIDEMIOLOGY

  • 1. Epidemiology
  • 2. Epidemiology (continued)
  • 3. Epidemiology (continued)

5. COMPETITIVE LANDSCAPE

  • 1. Competitive Landscape-Marketed and Pipeline Drugs in Pre-registration and Phase 3
  • 2. Competitive Landscape-Pipeline Drugs in Phase 1 and Phase 2
  • 3. Timeline of Product Launches/Approval
  • 4. Timeline of Patent Expiries
  • 5. Competitive Landscape-Pivotal Clinical Trials
  • 6. Competitive Landscape-Pivotal Clinical Trials (continued)

6. MARKETED PRODUCTS

  • 1. Marketed Products Synopsis
  • 2. Marketed Products Synopsis (continued)
  • 3. Marketed Products Synopsis (continued)
  • 4. Marketed Products Synopsis (continued)

7. PIPELINE DRUGS ANALYSIS

  • 1. Pipeline Synopsis
  • 2. Pipeline Synopsis (continued)
  • 3. Pipeline Synopsis (continued)
  • 4. Pipeline Synopsis (continued)
  • 5. Pipeline Synopsis (continued)
  • 6. Pipeline Synopsis (continued)
  • 7. Pipeline Synopsis (continued)
  • 8. Pipeline Synopsis (continued)
  • 9. Pipeline Synopsis (continued)
  • 10. Pipeline Synopsis (continued)
  • 11. Pipeline Synopsis (continued)
  • 12. Pipeline Synopsis (continued)
  • 13. Pipeline Synopsis (continued)
  • 14. Pipeline Synopsis (continued)
  • 15. Pipeline Synopsis (continued)
  • 16. Pipeline Synopsis (continued)
  • 17. Pipeline Synopsis (continued)

8. PRODUCT DASHBOARD OF RECENTLY APPROVED DRUGS AND LATE-STAGE PIPELINE DRUG CANDIDATES

  • 1. Product Dashboard: Tarceva® (Erlotinib)-Roche Group
  • 2. Product Dashboard: Gilotrif® (Afatinib)-Boehringer Ingelheim
  • 3. Product Dashboard: Avastin® (Bevacizumab)-Genentech Inc. (Roche Group)
  • 4. Product Dashboard: Alimta® (Pemetrexed)-Eli Lilly and Company
  • 5. Product Dashboard: XALKORI® (Crizotinib)-Pfizer Inc.
  • 6. Product Dashboard: AP26113-Ariad Pharmaceuticals, Inc.
  • 7. Product Dashboard: Necitumumab-Eli Lilly and Company
  • 8. Product Dashboard: Nivolumab-Bristol-Myers Squibb Company and Ono Pharmaceutical

9. CONCLUSIONS

  • 1. Conclusions
  • 2. Legal Disclaimer

10. APPENDIX

  • 1. About Lung Cancer
  • 2. About Lung Cancer (continued)

11. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition: Future of Your Company & Career
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top